Thursday, July 24, 2014

Manoj Venkiteshwar joins TearLab as VP of medical affairs

Manoj Venkiteshwar joins TearLab as VP of medical affairs

July 14, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) announced the appointment of Manoj Venkiteshwar to its senior management team in the newly created position of VP of medical affairs. Dr. Venkiteshwar’s mandate will be the development and execution of a comprehensive academic and key opinion leaders (KOL) management strategy for the company. He joins TearLab from his current position as […]

TearLab, Cancer Genetics in Feltl’s Top Idea List for H2-2014

TearLab, Cancer Genetics in Feltl’s Top Idea List for H2-2014

July 8, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) and Cancer Genetics (NASDAQ:CGIX) have been included in Feltl & Co.’s Top Ideal List for the second half of 2014. Analyst Ben Haynor rates both stocks as “strong buys.” His price target for TearLab is $10.50 and $18.50 for Cancer Genetics. He said TearLab has first-mover advantage in point-of-care diagnostics for […]

TearLab posts 70% jump in Q1 revenue

TearLab posts 70% jump in Q1 revenue

May 8, 2014 by · Leave a Comment 

Tweet First quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) totaled $4.2-million, up 70%, from $2.5-million a year ago. A total of 254 orders for TearLab systems were booked in the first quarter, of which 201 systems were under the company’s Masters Multi Unit Program, 40 were through its minimum use access programs, six were direct purchases […]

Survey finds high confidence in tear osmolarity testing

Survey finds high confidence in tear osmolarity testing

April 25, 2014 by · Leave a Comment 

Tweet A survey by Ophthalmic Consultants of Long Island conducted after TearLab (NASDAQ:TEAR; TSX:TLB) partnered with major dry eye organization, Sjögren’s Society, to promote Dry Eye Disease Awareness Month last year found a high degree of patient satisfaction in tear osmolarity testing. There were 278 eye clinics that participated in the survey and over 1,000 […]

Alcon’s Paul Smith joins TearLab as VP International

Alcon’s Paul Smith joins TearLab as VP International

April 21, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has appointed Paul Smith to its senior management team in the newly created position of VP, International. Mr. Smith’s mandate will be the development and execution of a comprehensive international business strategy for TearLab. He joins TearLab from his current position as global marketing manager within the surgical cataract franchise at […]

TearLab Q4 revenue jumps 176%

TearLab Q4 revenue jumps 176%

March 13, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has reported fourth quarter revenue of $4.4- million, up 176%, from $1.6-million for the same period in 2012. A total of 359 orders for TearLab systems were booked in the fourth quarter, of which 259 systems were under the company’s Masters Multi Unit Program, 72 were through its minimum use access […]

TearLab to acquire AOA’s OcuHub platform

TearLab to acquire AOA’s OcuHub platform

February 18, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has signed a non-binding term sheet to purchase the assets of the OcuHub business unit from AOAExcel, the for-profit subsidiary of the American Optometric Association (“AOA”). OcuHub, powered by AT&T and Covisint, is an established compliant technology platform designed to securely connect eye doctors, patients, healthcare organizations and payers. The acquisition […]

TearLab issues prelim Q4 revenue and gives 2014 revenue guidance

TearLab issues prelim Q4 revenue and gives 2014 revenue guidance

February 3, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) said preliminary total revenue for the fourth quarter of 2013 is expected to be about $4.5-million, bringing expected full year 2013 revenue to about $14.7-million.   The preliminary expected revenue in the fourth quarter reflects an increase of about 181%, compared with revenue of $1.6-million in the fourth quarter of 2012. The […]

In conversation with Elias Vamvakas

In conversation with Elias Vamvakas

January 28, 2014 by · Leave a Comment 

Tweet As CEO of San Diego-based TearLab (NASDAQ:TEAR; TSX:TLB), eye care entrepreneur, Elias Vamvakas, has scored another home run with a medical device for the diagnosis and management of dry eye disease (DED). The TearLab Osmolarity System uses a novel lab-on-a-chip approach that requires less than 50 nanoliters of tear fluid in order to measure […]

TearLab included in Feltl’s 2014 Top Idea List

TearLab included in Feltl’s 2014 Top Idea List

January 2, 2014 by · Leave a Comment 

Tweet Feltl & Co. has released its 2014 Top Idea List, which included TearLab (NASDAQ:TEAR; TSX:TLB). Analyst Ben Haynor writes that TearLab has first-mover advantage in point-of-care diagnostics for dry eye disease (DED). The TearLab Osmolarity System is a lab-on-a-chip system that provides a quantitative measure (osmolarity) of DED in less than 30 seconds. He […]

Next Page »

Email Newsletters with Constant Contact
Google+